Chronix Biomedical opens state-of-the-art mass sequencing laboratory to provide medical researchers with personal biomarkers in human disease

Myriad Genetics Licenses Novel Technology From Chronix Biomedical

Chronix Biomedical and Hemispherx Biopharma jointly file patent application for a blood test for chronic fatigue syndrome (cfs)

CEO highlights how Chronix’s unique blood tests can enable early cancer diagnosis and personalized treatment at Payor Oncology Conference

New concerns about mad cow disease highlight importance of Chronix blood test that can detect bse before symptoms appear

Chronix Biomedical announces completion of Series E Financing

Chronix Biomedical adds state-of-the-art mass sequencing capabilities to accelerate development of its dna biomarkers for early detection of cancer

Data presented at ASCO show Chronix Biomedical’s dna blood tests detect breast and prostate cancer with 92% sensitivity and 100% specificity

Chronix Biomedical to launch cancer detection and monitoring service at ASCO to advance clinical research using its apoptotic dna blood test

Chronix to present data at ASCO that could revolutionize the diagnostic paradigm for cancer

Chronix Biomedical partners with University of Calgary to commercialize serum dna-based blood test for mad cow disease

Newly published data shows Chronix Biomedical’s serum dna assays can monitor disease activity and treatment response in multiple sclerosis

Newly published data shows Chronix Biomedical’s serum dna assays can detect early-stage breast cancer

Chronix Biomedical appoints industry veteran Paul E. Freiman as chairman

Newly published study using Chronix technology confirms serum dna can identify the early presence of disease

Chronix Biomedical says three recent studies support the utility of circulating dna as novel diagnostics for human cancer, mad cow disease and other conditions